Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and ...

TAGRISSO ® (osimertinib) Important Safety Information There are no contraindications for TAGRISSO Interstitial Lung Disease (ILD)/Pneumonitis occurred in 3.5% and was fatal in 0.6% of 833 ...

Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine ...

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non ...

Osimertinib (Tagrisso, AstraZeneca) cemented its role as front-line treatment of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) in last year's FLAURA trial.